Does the presence of anti-CarP antibodies predict disease development and radiological progression in individuals in the pre-symptomatic phase of rheumatoid arthritis?
Anti-CarP antibodies serve as an independent biomarker for predicting disease development and worse radiological progression in rheumatoid arthritis.
The results indicate that anti-CarP antibodies are associated with disease development, even after adjusting for the presence of different ACPA fine specificities, and in anti-CCP2 negative individuals and contribute to the identification of a subset of patients with worse radiological progression of the disease independent of ACPA.
Brink et al. (Wed,) studied this question.